Lipopolysaccharide binding protein is a potential marker for invasive bacterial infections in children

Pediatric Infectious Disease Journal

Volumn 26, Issue 2, 2007, Pages 159-162

  Ubenauf, Katja M ^a   Krueger, Marcus ^a   Henneke, Philipp ^a   Berner, Reinhard ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Bacterial infection; Children; Lipopolysaccharide binding protein (LBP); Meningitis

Indexed keywords

ANTIBIOTIC AGENT; INTERLEUKIN 8; LIPOPOLYSACCHARIDE BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; BACTERIAL MENINGITIS; BACTERIUM DETECTION; BLOOD CULTURE; BLOOD SAMPLING; CEREBROSPINAL FLUID; CHEMOLUMINESCENCE; CHILD; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HUMAN; HYPOTHESIS; INFANT; JUVENILE RHEUMATOID ARTHRITIS; MALE; NEISSERIA MENINGITIDIS; NEUROLOGIC DISEASE; PEDIATRICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; STREPTOCOCCUS PNEUMONIAE; VIRUS INFECTION;

ACUTE-PHASE PROTEINS; ADOLESCENT; BIOLOGICAL MARKERS; CARRIER PROTEINS; CEREBROSPINAL FLUID; CHEMILUMINESCENT MEASUREMENTS; CHILD; CHILD, PRESCHOOL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; IMMUNOASSAY; INFANT; INTERLEUKIN-8; MEMBRANE GLYCOPROTEINS; MENINGITIS, BACTERIAL; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; PNEUMOCOCCAL INFECTIONS; SEPSIS; SERUM; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846587000     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000253064.88722.6d     Document Type: Article

References (19)

1. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003;115:529-535.
2. Cauwels A, Frei K, Sansano S, et al. The origin and function of soluble CD14 in experimental bacterial meningitis. J Immunol. 1999;162:4762-4772.
3. Dumont RA, Car BD, Voitenok NN, et al. Systemic neutralization of interleukin-8 markedly reduces neutrophilic pleocytosis during experimental lipopolysaccharide-induced meningitis in rabbits. Infect Immun. 2000;68:5756-5763.
4. Froon AH, Dentener MA, Greve JW, Ramsay G, Buurman WA. Lipopolysaccharide toxicity-regulating proteins in bacteremia. J Infect Dis. 1995;171:1250-1257.
5. Haziot A, Tsuberi BZ, Goyert SM. Neutrophil CD14: Biochemical properties and role in the secretion of tumor necrosis factor-alpha in response to lipopolysaccharide. J Immunol. 1993;150:5556-5565.
6. Leturcq DJ, Moriarty AM, Talbott G, Winn RK, Martin TR, Ulevitch RJ. Therapeutic strategies to block LPS interactions with its receptor. Prog Clin Biol Res. 1995;392:473-477.
7. Le Roy D, Di Padova F, Tees R, et al. Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14. J Immunol. 1999;162:7454-7460.
8. Waage A, Halstensen A, Shalaby R, Brandtzaeg P, Kierulf P, Espevik T. Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response. J Exp Med. 1989;170:1859-1867.
9. Berner R, Furll B, Stelter F, Drose J, Muller HP, Schutt C. Elevated levels of lipopolysaccharide-binding protein and soluble CD14 in plasma in neonatal early-onset sepsis. Clin Diagn Lab Immunol. 2002;9:440-445.
10. Orlikowsky TW, Trug C, Neunhoeffer F, Deperschmidt M, Eichner M, Poets CF. Lipopolysaccharide-binding protein in noninfected neonates and those with suspected early-onset bacterial infection. J Perinatol. 2006;26:115-119.
11. Pavcnik-Arnol M, Hojker S, Derganc M. Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: Comparison with procalcitonin, interleukin-6, and C-reactive protein. Intensive Care Med. 2004;30:1454-1460.
12. Froon AH, Bemelmans MH, Greve JW, van der Linden CJ, Buurman WA. Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: Correlation with plasma creatinine values. Crit Care Med. 1994;22:803-809.
13. Gallay P, Barras C, Tobias PS, Calandra T, Glauser MP, Heumann D. Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS. J Infect Dis. 1994;170:1319-1322.
14. Lamping N, Dettmer R, Schroder NW, et al. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest. 1998;101:2065-2071.
15. Opal SM, Scannon PJ, Vincent JL, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999;180:1584-1589.
16. Schumann RR, Zweigner J. A novel acute-phase marker: Lipopolysaccharide binding protein (LBP). Clin Chem Lab Med. 1999;37:271-274.
17. Vreugdenhil AC, Snoek AM, van't Veer C, Greve JW, Buurman WA. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest. 2001;107:225-234.
18. Wurfel MM, Wright SD. Lipopolysaccharide (LPS) binding protein catalyzes binding of LPS to lipoproteins. Prog Clin Biol Res. 1995;392:287-295.
19. Kleine TO, Zwerenz P, Zofel P, Shiratori K. New and old diagnostic markers of meningitis in cerebrospinal fluid (CSF). Brain Res Bull. 2003;61:287-297.